Reconstitution of XXXX after high-dose chemotherapy by autologous progenitor cells generated ex vivo.

@entity1 @entity650 @entity6826 @entity1356 @entity5 @entity3003 @entity1259 @entity2879 @entity1583 @entity2772 @entity1260 @entity2280 @entity1210
BACKGROUND: Autologous peripheral-blood progenitor cells can restore @entity1210 after high-dose chemotherapy in @entity1 with solid @entity5 or @entity1583 . We investigated the ability of peripheral-blood progenitor cells generated ex vivo to restore @entity1210 in @entity1 with @entity5 who have undergone high-dose chemotherapy. METHODS: Ten @entity1 who had received high-dose chemotherapy were given transplants of autologous progenitor cells that had been generated ex vivo. We used 11 million @entity2280 + hematopoietic progenitor cells as the starting population for the cell growth. This number corresponds to less than 10 percent of the usual preparation of peripheral-blood @entity2280 + mononuclear cells used in leukapheresis. The @entity2280 + cells were grown in medium containing autologous plasma, recombinant @entity1 @entity6826 , @entity1356 , @entity2772 , @entity650 , and erythropoietin. RESULTS: No toxic effects were observed with the infusion of the generated cells. The cells promoted a rapid and sustained hemopoietic recovery when transplanted after treatment with high-dose @entity2879 (1500 mg per square meter of body-surface area), @entity1260 (12 g per square meter), @entity3003 (750 mg per square meter), and @entity1259 (150 mg per square meter). The pattern of hematopoietic reconstitution was identical to that in historical controls treated with unseparated mononuclear cells or positively selected @entity2280 + cells. CONCLUSIONS: A small number of peripheral-blood @entity2280 + cells, when grown ex vivo, can supply a population of hematopoietic precursors that have the ability to restore blood formation in @entity1 treated with high doses of chemotherapy. This method, which requires only a small volume of the @entity1 's blood, may reduce the risk of @entity5 -cell contamination, circumvent the need for leukapheresis, and allow repeated cycles of high-dose chemotherapy.
